BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Fresenius SE & Co KGaA

Gesloten

SectorGezondheidszorg

39.86 -0.2

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

39.7

Max

40.25

Belangrijke statistieken

By Trading Economics

Inkomsten

-48M

271M

Verkoop

264M

5.6B

K/W

Sectorgemiddelde

24.381

57.333

Winstmarge

4.813

Werknemers

176,486

EBITDA

-33M

724M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+17.39% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.1B

22B

Vorige openingsprijs

40.06

Vorige sluitingsprijs

39.86

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Fresenius SE & Co KGaA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 feb 2025, 13:37 UTC

Marktinformatie

European Stocks on Track for Record Close as Earnings Lift Mood -- Market Talk

5 jun 2024, 12:18 UTC

Marktinformatie

Fresenius Helios Guidance Lift Should Drive Consensus Upgrades -- Market Talk

Peer Vergelijking

Prijswijziging

Fresenius SE & Co KGaA Prognose

Koersdoel

By TipRanks

17.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 46.78 EUR  17.39%

Hoogste 56.9 EUR

Laagste 42 EUR

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fresenius SE & Co KGaA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Technische score

By Trading Central

39.5 / 39.92Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Fresenius SE & Co KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.